New hope for myeloma: experimental drug takes on standard combo

NCT ID NCT07452198

Recruiting now Disease control Sponsor: Genrix (Shanghai) Biopharmaceutical Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 3 trial is testing a new drug called GR1803 against a standard three-drug combination (daratumumab, pomalidomide, and dexamethasone) in people with multiple myeloma that has come back after 1 to 3 prior treatments. About 358 participants will be randomly assigned to receive either GR1803 or the standard combo. The main goal is to see which treatment keeps the cancer from growing longer.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: GR1803 injection (a drug given intravenously)
What this could lead to: If GR1803 works better than the current standard, it could offer a new treatment option for people with multiple myeloma that has come back after earlier therapies.
What could go wrong: This is an early Phase 3 trial, so results are not yet known. The new drug may not be more effective or could have unexpected side effects compared to the existing combination.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

plasma cell myeloma refractory plasma cell neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MULTIPLE MYELOMA

Contacts and locations

Locations

Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences
RECRUITING

Tianjin, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.